BIOMAT Database Logo BIOMAT Database Logo

Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. 1991

P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Department of Allergy and Allied Respiratory Disorders, UMDS, Guy's Hospital, London, UK.

Urinary leukotriene E4 (LTE4) concentrations have been measured in six asthmatic patients with aspirin sensitivity and in five asthmatic subjects tolerant of aspirin, before and after provocation with aspirin or placebo. Aspirin-sensitive subjects showed an average 21% fall in FEV1 after aspirin challenge whereas control individuals had a 2% fall in FEV1 after ingestion of 100 mg aspirin. The resting urinary LTE4 concentrations in asthmatic subjects sensitive to aspirin were 243 pg/mg creatinine (range 50 to 1,041), and these were on average sixfold greater than those in control asthmatic subjects. Further, there was a mean fourfold increase in urinary LTE4 levels at 3 to 6 h after aspirin, but not placebo, challenge in aspirin-sensitive asthmatic subjects that was not seen in the control asthmatic individuals. Leukotriene release may play a central role in the mechanisms of asthmatic attacks produced by aspirin ingestion.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D001986 Bronchial Spasm Spasmodic contraction of the smooth muscle of the bronchi. Bronchospasm,Bronchial Spasms,Bronchospasms,Spasm, Bronchial,Spasms, Bronchial
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic

Related Publications

P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects.
November 1993, The European respiratory journal,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma.
May 1995, American journal of respiratory and critical care medicine,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Early increase in urinary leukotriene E4 (LTE4) is dependent on allergen dose inhaled during bronchial challenge in asthmatic subjects.
December 1999, Allergy,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Release of urinary leukotriene E4 in asthmatic subjects: a review.
January 1994, Advances in prostaglandin, thromboxane, and leukotriene research,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Urinary leukotriene E4 after exercise challenge in children with asthma.
June 1992, The Journal of allergy and clinical immunology,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma.
April 1997, Allergy,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
[Aspirin induced asthma, urinary leukotriene E4 and zafirlukast].
January 2002, Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993),
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge.
August 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Inactivation of leukotriene C4 in the airways and subsequent urinary leukotriene E4 excretion in normal and asthmatic subjects.
November 1993, The American review of respiratory disease,
P E Christie, and P Tagari, and A W Ford-Hutchinson, and S Charlesson, and P Chee, and J P Arm, and T H Lee
Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects.
February 1987, The American review of respiratory disease,
Copied contents to your clipboard!